#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17290	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2453	864.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1642	1642	C	1062	C,T,A	1059,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29094	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4209	863.1	0	.	n	.	0	T695C	SNP	695	695	T	1335	1335	C	1036	C,G	1035,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29094	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4209	863.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1977	1977	A	1133	A,T	1131,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29094	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4209	863.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2611	2611	C	997	C	997	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29094	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4209	863.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2685	2685	A	968	A	968	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29094	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4209	863.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3237	3237	C	1070	C,G	1069,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	2508	folP	855	855	100.0	folP.l15.c4.ctg.1	1990	156.9	1	SNP	p	R229S	0	.	.	685	687	CGC	1229	1231	CGC	244;248;252	C;G;C,G	244;248;251,1	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5920	gyrA	2751	2751	99.89	gyrA.l6.c30.ctg.1	3928	188.1	1	SNP	p	S91F	0	.	.	271	273	TCC	895	897	TCC	238;240;239	T,A;C;C,T	236,2;240;238,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5920	gyrA	2751	2751	99.89	gyrA.l6.c30.ctg.1	3928	188.1	1	SNP	p	D95N	0	.	.	283	285	GAC	907	909	GAC	228;228;227	G;A;C,T	228;228;226,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5920	gyrA	2751	2751	99.89	gyrA.l6.c30.ctg.1	3928	188.1	1	SNP	p	D95G	0	.	.	283	285	GAC	907	909	GAC	228;228;227	G;A;C,T	228;228;226,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	2450	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1787	171.0	1	SNP	p	G45D	1	.	.	133	135	GAC	721	723	GAC	278;281;281	G,A;A,T,C;C	277,1;279,1,1;281	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1346	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1426	117.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	6000	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3499	214.0	1	SNP	p	D86N	0	.	.	256	258	GAC	857	859	GAC	258;259;257	G,T;A,G,C;C,A	257,1;257,1,1;256,1	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	6000	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3499	214.0	1	SNP	p	S88P	0	.	.	262	264	TCC	863	865	TCC	259;257;258	T,C,A;C,A;C	257,1,1;256,1;258	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4770	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3091	192.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1730	1732	GGC	253;252;253	G,A;G,A;C,A	252,1;251,1;252,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1534	1536	GCA	279;281;285	G;C;A	279;281;285	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1537	1539	ATC	281;280;279	A;T;C,T	281;280;278,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1549	1551	GTG	284;284;284	G;T,C;G	284;282,2;284	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1549	1551	GTG	284;284;284	G;T,C;G	284;282,2;284	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2053	2055	ACC	256;255;252	A;C;C	256;255;252	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2107	2109	GCG	243;243;243	G;C;G	243;243;243	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2107	2109	GCG	243;243;243	G;C;G	243;243;243	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2230	2232	GGC	267;266;265	G,T;G,T;C	266,1;265,1;265	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2239	2241	GGC	261;261;262	G,A;G,A;C	260,1;259,2;262	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4590	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2852	200.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2257	2259	CTG	250;248;248	C,T;T;G	249,1;248;248	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6648	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3606	229.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1927	1929	CCG	274;274;273	C;C,G,A;G	274;272,1,1;273	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2285	150.0	0	.	p	.	0	S22G	NONSYN	64	66	AGC	633	635	GGC	216;211;212	G;G;C,T	216;211;211,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2285	150.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	815	815	C	180	C,T	179,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	S45N	NONSYN	133	135	AGT	652	654	AAT	290;294;291	A;A;T	290;294;291	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	877	879	AAG	313;308;308	A,G,C;A;G	311,1,1;308;308	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	D121G	NONSYN	361	363	GAC	880	882	GGC	307;308;310	G,T,A;G;C	304,2,1;308;310	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	946	948	CAA	326;328;332	C,T,A;A;A,C	324,1,1;328;331,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1153	1155	GAT	282;280;281	G;A;T	282;280;281	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1156	1158	GGT	278;280;277	G,A;G,C,A;T,C	277,1;277,2,1;276,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	Q214H	NONSYN	640	642	CAA	1159	1161	CAT	274;279;276	C;A;T	274;279;276	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	V215T	NONSYN	643	645	GTT	1162	1164	ACT	274;273;272	A,T,C;C,G;T	272,1,1;272,1;272	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1171	1173	ATG	273;272;269	A;T;G,T	273;272;268,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1288	1290	ACG	274;273;271	A;C;G	274;273;271	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1294	1296	GTT	271;269;271	G;T,G,C;T	271;266,2,1;271	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3534	porB1b	1047	1047	98.38	porB1b.l15.c4.ctg.1	2133	206.3	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1408	1410	AAC	301;299;302	A,C;A;C,T	300,1;299;301,1	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12334	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5527	278.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1900	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1495	157.9	1	SNP	p	V57M	1	.	.	169	171	ATG	793	795	ATG	344;342;341	A;T,C;G	344;341,1;341	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
